Genentech Usa, Inc.

Genentech USA, Inc., a foreign-owned pharmaceutical and biotechnology manufacturer headquartered in South San Francisco, California, supplies critical pharmaceuticals and biologics to the federal government exclusively as a prime contractor across defense and civilian health agencies, competing through open-competition delivery orders and blanket purchase agreements with no set-aside designations. The company is a subsidiary of Foundation Medicine, Inc., and operates across NAICS 325412 (Pharmaceutical Preparation Manufacturing) and 325414 (Medicinal and Botanical Manufacturing), with PSC concentration in Drugs and Biologicals procurement.

Genentech's federal footprint is dominated by small-unit, high-frequency delivery orders for specialized antiviral medications and biologics. Representative examples include a $74.97 million delivery order from the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response (ASPR) for Xofluza (baloxavir marboxil) 40mg and 80mg tablets awarded September 26, 2025 (ultimate completion September 29, 2027); a $45.1 million ASPR delivery order for Oseltamivir Phosphate (Tamiflu) 30mg and 75mg capsules awarded January 30, 2025; and a $21.99 million ASPR delivery order for Xofluza awarded September 30, 2024. Across its delivery-order footprint, Genentech supplies TNKase (tenecteplase) 50 mg kits, Activase (alteplase) 50 mg vials, Tamiflu in multiple formulations, and clonazepam and diazepam tablets to the Defense Logistics Agency Troop Support Medical (DLA). All work is performed at Genentech's South San Francisco facility.

Customer concentration is extreme and skewed toward a single large vehicle. The top five customer agencies by award count account for 97% of all awards. By potential value, the Department of Veterans Affairs Veterans Integrated Service Network 12 anchors the portfolio with four awards totaling $13.71 billion in combined potential value, driven entirely by a single $4.927 billion Federal Supply Schedule contract (FSS-61-IB, Pharmaceuticals and Drugs) awarded September 15, 2023 through September 14, 2028. The DLA Troop Support Medical dominates by award count (470 awards, $195.1 million combined potential value) through rapid, small-value delivery orders, while ASPR represents the second-largest dollar concentration ($202.1 million across five awards). This divergence reflects two distinct ordering patterns: tactical replenishment of common stock items through DLA's indefinite-delivery vehicle, and strategic national-stockpile procurement of antiviral treatments through ASPR's GSA Schedule.

Genentech holds positions on five parent contract vehicles that anchor all recent task-order activity. The Indefinite Delivery Contract SPE2DP18D0011 carries 211 task orders worth $16.6 million combined potential value; SPM2D013D0005 carries 140 task orders worth $3.4 million; SPE2DP16D0008 carries 68 task orders worth $34 million; and SPE2D021D0005 carries 47 task orders worth $3 million. The Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) under the VA generates 14 task orders worth $205.2 million combined potential value, predominantly flowing through ASPR for pandemic-response and national-stockpile initiatives. All vehicles are full-and-open, non-set-aside procurements.

Activity has remained flat to modestly declining — ten awards in 2022, eleven in 2023, nine in 2024, eleven in 2025, and two year-to-date in 2026 — with a recompete cliff of only one award ($75 million combined potential value) completing within the next twenty-four months. This low-velocity recompete exposure reflects the absence of performance periods ending in the near term across Genentech's largest vehicles; the VA FSS contract runs through September 2028, and the DLA indefinite-delivery vehicles extend through 2031. Genentech operates exclusively as a prime contractor (100% of awards) with no subcontract footprint.

Genentech's portfolio of 508 awards totals $14.24 billion in combined potential value with $225.2 million in combined dollars obligated (2% of potential), a ratio reflecting the large ceiling values on open-ended supply schedules and indefinite-delivery vehicles against modest near-term invoice activity. The vendor's federal posture centers on assured supply of critical-care pharmaceuticals and antivirals supporting DoD medical readiness, federal stockpiling, and civilian healthcare preparedness, executed through pre-established pricing under GSA schedules and long-standing DLA indefinite-delivery contracts rather than competitive procurement cycles.